Skip to main content
Top
Published in: BMC Pregnancy and Childbirth 1/2024

Open Access 01-12-2024 | Human Immunodeficiency Virus | Research

Epidemiological and virological surveillance of the prevention of mother-to-child transmission of HIV among pregnant women in Togo

Authors: Kokou Tegueni, Fifonsi Adjidossi Gbeasor-Komlanvi, Oumarou I. Wone Adama, Arnold Junior Sadio, Amivi Phyllis Amenyah-Ehlan, Claver Anoumou Dagnra, Didier Koumavi Ekouevi

Published in: BMC Pregnancy and Childbirth | Issue 1/2024

Login to get access

Summary

Background

In 2015, Togo introduced the “test-and-treat” strategy for the prevention of mother-to-child transmission (PMTCT) of HIV. Pediatric HIV infection remains a public health problem in Togo, with a mother-to-child transmission (MTCT) rate of 3.6% in 2020. This study aimed to estimate cases of HIV seroconversion during pregnancy and to identify pregnant women at high risk of transmitting HIV to their children in Lomé, Togo.

Methods

A descriptive cross-sectional study was carried out from 18 March to 22 May 2022 among women who had given birth in five maternity units providing PMTCT services in Lomé. Umbilical cord blood samples were taken from the maternal side by midwives after delivery. HIV serology was performed in the laboratory using the Alere™ HIV Combo SET and First Response HIV 1–2. Card Test version 2.0. A sample was considered positive if both tests were positive. The HIV-1 viral load in HIV-1-positive samples was measured using Cobas/Roche 4800 equipment. Information on the women was extracted from maternal antenatal records and antenatal consultation registers.

Results

A total of 3148 umbilical cord blood samples (median maternal age: 28 years (interquartile range [24–32]) were collected. Among them, 99.3% (3145/3148) had presented for at least one antenatal clinic visit before giving birth, and 78.7% (2456/3122) had presented for at least four visits. One hundred and twenty-one (121) cord samples were HIV-1 positive, representing a seroprevalence of 3.8% (95% CI = [3.2–4.6]). Among them, 67.8% (82/121) were known HIV-positive before the current pregnancy, 29.7 (36/121) were diagnosed as HIV-positive at the antenatal visits and 2.5% (3/121) were diagnosed as HIV-positive in the delivery room. Of the HIV-positive women, 85.9% (104/121) were on ARV treatment before delivery. The viral load was < 1000 copies/ml in 97.5% (118/121) cases.

Conclusion

This study explored the virologic and epidemiological aspects of HIV among pregnant women in Togo. The results show significant viral suppression at delivery in women ART. Surveillance based on umbilical cord blood specimen screening is an interesting approach for monitoring the effectiveness of PMTCT programmes.
Literature
1.
go back to reference Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data – 2021. Geneva: UNAIDS; 2021. p. 468. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data – 2021. Geneva: UNAIDS; 2021. p. 468.
5.
go back to reference Turan JM, Onono M, Steinfeld RL, Shade SB, Owuor K, Washington S et al. Implementation and Operational Research: Effects of Antenatal Care and HIV Treatment Integration on Elements of the PMTCT Cascade: Results From the SHAIP Cluster-Randomized Controlled Trial in Kenya. J Acquir Immune Defic Syndr. 1999. 2015;69:e172-181. Turan JM, Onono M, Steinfeld RL, Shade SB, Owuor K, Washington S et al. Implementation and Operational Research: Effects of Antenatal Care and HIV Treatment Integration on Elements of the PMTCT Cascade: Results From the SHAIP Cluster-Randomized Controlled Trial in Kenya. J Acquir Immune Defic Syndr. 1999. 2015;69:e172-181.
7.
go back to reference World Health Organization (WHO). Global Guidance on Criteria and processes for validation: elimination of Mother-to-child transmission of HIV and Syphilis. 3rd ed. Geneva: WHO; 2021. p. 86. World Health Organization (WHO). Global Guidance on Criteria and processes for validation: elimination of Mother-to-child transmission of HIV and Syphilis. 3rd ed. Geneva: WHO; 2021. p. 86.
9.
go back to reference de la Ministère. Santé et de l’Hygiène Publique et de l’Accès Universel aux Soins (MSHPAUS), Programme National De Lutte Contre L’infection à VIH/Sida, les Hépatites virales et les infections Sexuellement Transmissibles (PNLS-HV-IST). Rapport Annuel 2020 des activités du PNLS-HV-IST. MSHPAUS/PNLS-HV-IST; 2021. p. 56. de la Ministère. Santé et de l’Hygiène Publique et de l’Accès Universel aux Soins (MSHPAUS), Programme National De Lutte Contre L’infection à VIH/Sida, les Hépatites virales et les infections Sexuellement Transmissibles (PNLS-HV-IST). Rapport Annuel 2020 des activités du PNLS-HV-IST. MSHPAUS/PNLS-HV-IST; 2021. p. 56.
10.
go back to reference de la Ministère. Santé et de l’Hygiène Publique et de l’Accès Universel aux Soins (MSHPAUS), Programme National De Lutte Contre L’infection à VIH/Sida, les Hépatites virales et les infections Sexuellement Transmissibles (PNLS-HV-IST). Rapport Annuel 2021 des activités du PNLS-HV-IST. MSHPAUS/PNLS-HV-IST; 2022. p. 63. de la Ministère. Santé et de l’Hygiène Publique et de l’Accès Universel aux Soins (MSHPAUS), Programme National De Lutte Contre L’infection à VIH/Sida, les Hépatites virales et les infections Sexuellement Transmissibles (PNLS-HV-IST). Rapport Annuel 2021 des activités du PNLS-HV-IST. MSHPAUS/PNLS-HV-IST; 2022. p. 63.
12.
go back to reference Stringer EM, Ekouevi DK, Coetzee D, Tih PM, Creek TL, Stinson K, et al. Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA. 2010;304(3):293–302.CrossRefPubMed Stringer EM, Ekouevi DK, Coetzee D, Tih PM, Creek TL, Stinson K, et al. Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA. 2010;304(3):293–302.CrossRefPubMed
14.
go back to reference Ford CE, Coetzee D, Winston J, Chibwesha CJ, Ekouevi DK, Welty TK, et al. Maternal decision-making and Uptake of Health Services for the Prevention of Mother-to-child HIV Transmission: a secondary analysis. Matern Child Health J. 2019;23(1):30–8.CrossRefPubMedPubMedCentral Ford CE, Coetzee D, Winston J, Chibwesha CJ, Ekouevi DK, Welty TK, et al. Maternal decision-making and Uptake of Health Services for the Prevention of Mother-to-child HIV Transmission: a secondary analysis. Matern Child Health J. 2019;23(1):30–8.CrossRefPubMedPubMedCentral
16.
go back to reference Kalk E, Slogrove A, Speert D, Bettinger J, Cotton M, Esser M. HIV sero-conversion during late pregnancy – when to retest. South Afr J HIV Med. 2013;14(2):90–2.CrossRef Kalk E, Slogrove A, Speert D, Bettinger J, Cotton M, Esser M. HIV sero-conversion during late pregnancy – when to retest. South Afr J HIV Med. 2013;14(2):90–2.CrossRef
19.
go back to reference O Olakunde B, Wakdok S, Olaifa Y, Agbo F, Essen U, Ojo M, et al. Improving the coverage of prevention of mother-to-child transmission of HIV services in Nigeria: should traditional birth attendants be engaged? Int J STD AIDS. 2018;29:687–90.CrossRefPubMed O Olakunde B, Wakdok S, Olaifa Y, Agbo F, Essen U, Ojo M, et al. Improving the coverage of prevention of mother-to-child transmission of HIV services in Nigeria: should traditional birth attendants be engaged? Int J STD AIDS. 2018;29:687–90.CrossRefPubMed
20.
go back to reference World Health Organization (WHO). WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: WHO; 2016. p. 176. World Health Organization (WHO). WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: WHO; 2016. p. 176.
22.
go back to reference World Health Organization (WHO). Delivering HIV test results and messages for re-testing and counselling in adults. Geneva: WHO; 2010. p. 32. World Health Organization (WHO). Delivering HIV test results and messages for re-testing and counselling in adults. Geneva: WHO; 2010. p. 32.
23.
go back to reference Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2021;397(10281):1276–92.CrossRefPubMedPubMedCentral Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2021;397(10281):1276–92.CrossRefPubMedPubMedCentral
24.
go back to reference Brown JA, Nsakala BL, Mokhele K, Rakuoane I, Muhairwe J, Urda L, et al. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study). HIV Med. 2022;23:287–93.CrossRefPubMed Brown JA, Nsakala BL, Mokhele K, Rakuoane I, Muhairwe J, Urda L, et al. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study). HIV Med. 2022;23:287–93.CrossRefPubMed
25.
go back to reference Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la transmission Mère-Enfant. Lancet. 1999;353(9155):786–92.CrossRefPubMed Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la transmission Mère-Enfant. Lancet. 1999;353(9155):786–92.CrossRefPubMed
Metadata
Title
Epidemiological and virological surveillance of the prevention of mother-to-child transmission of HIV among pregnant women in Togo
Authors
Kokou Tegueni
Fifonsi Adjidossi Gbeasor-Komlanvi
Oumarou I. Wone Adama
Arnold Junior Sadio
Amivi Phyllis Amenyah-Ehlan
Claver Anoumou Dagnra
Didier Koumavi Ekouevi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pregnancy and Childbirth / Issue 1/2024
Electronic ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-024-06435-w

Other articles of this Issue 1/2024

BMC Pregnancy and Childbirth 1/2024 Go to the issue